Literature DB >> 8543084

Crossed polarising filters to measure relative afferent pupillary defects: reproducibility, correlation with neutral density filters and use in central retinal vein occlusion.

A Ramsay1, T H Williamson, S Parks, D Keating.   

Abstract

Measurement of a relative afferent pupillary defect (RAPD) can be carried out by attenuation of light received by the normal eye during the swinging flashlight test. Such measurements may be useful in the management of central retinal vein occlusion (CRVO). In this study a method employing cross polarised filters (CPFs) was tested for reproducibility. In addition the pattern of attenuation of light was compared with that by neutral density filters (NDFs). Finally, the method was used to investigate 74 patients with CRVO. The method was reproducible (8.7% variation) and showed exponential attenuation of light (in contrast to linear attenuation by the NDFs). In unilateral CRVO a sensitivity of 71% and specificity of 69% for the risk of iris neovascularisation was determined by the presence of RAPD requiring 20 degrees of rotation of the CPFs. It is concluded that CPFs provide a useful alternative to NDFs for the measurement of RAPD and have some advantages. They can be employed in the clinical management of patients with CRVO.

Entities:  

Mesh:

Year:  1995        PMID: 8543084     DOI: 10.1038/eye.1995.151

Source DB:  PubMed          Journal:  Eye (Lond)        ISSN: 0950-222X            Impact factor:   3.775


  3 in total

1.  Quantifying relative afferent pupillary defects using a Sbisa bar.

Authors:  A McCormick; R Bhola; L Brown; D Squirrel; J Giles; I Pepper
Journal:  Br J Ophthalmol       Date:  2002-09       Impact factor: 4.638

Review 2.  Central retinal vein occlusion: what's the story?

Authors:  T H Williamson
Journal:  Br J Ophthalmol       Date:  1997-08       Impact factor: 4.638

3.  Quantification of relative afferent pupillary defects induced by posterior sub-Tenon's, peribulbar, and retrobulbar anaesthetics.

Authors:  A S Ramsay; N Ray-Chaudhuri; M Dayan; D Walshaw
Journal:  Br J Ophthalmol       Date:  2001-12       Impact factor: 4.638

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.